Mesocarb
Parkinson's Disease
Key Facts
About Melior Pharmaceuticals
Melior Pharmaceuticals is a private, pre-revenue biotech founded in 2005 that utilizes a unique drug repurposing platform to advance a de-risked clinical pipeline. Its lead assets are Tolimidone, a lyn kinase activator in Phase 2b for Type 2 Diabetes and early-stage for NASH, and Mesocarb, a dopamine reuptake inhibitor in development for Parkinson's Disease and Sleep Disorders. The company's strategy leverages existing clinical safety data to potentially accelerate development and reduce risk. Melior is seeking partnerships to advance its programs through later-stage clinical trials.
View full company profileAbout Melior Pharmaceuticals
Melior Pharmaceuticals is a private, pre-revenue biotech founded in 2005 that utilizes a unique drug repurposing platform to advance a de-risked clinical pipeline. Its lead assets are Tolimidone, a lyn kinase activator in Phase 2b for Type 2 Diabetes and early-stage for NASH, and Mesocarb, a dopamine reuptake inhibitor in development for Parkinson's Disease and Sleep Disorders. The company's strategy leverages existing clinical safety data to potentially accelerate development and reduce risk. Melior is seeking partnerships to advance its programs through later-stage clinical trials.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |